Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
KUAISHOU-W
01024
5
JD HEALTH
06618
| (FY)Mar 31, 2025 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 2.95%111.01B | 2.04%107.83B | -2.75%27.93B | -0.92%27.41B | 4.91%26.3B | 8.14%26.2B | 17.27%105.67B | 18.41%28.72B | 22.23%27.66B | 20.11%25.07B |
| Cost of revenue | 4.09%93.91B | -0.92%90.22B | -2.48%23.24B | -7.68%23.4B | -1.80%21.38B | 10.39%22.19B | 19.44%91.06B | 14.74%23.83B | 34.60%25.35B | 21.28%21.78B |
| Gross profit | -2.90%17.1B | 20.51%17.61B | -4.13%4.69B | 73.17%4B | 49.36%4.91B | -2.81%4.01B | 5.35%14.61B | 40.21%4.89B | -39.14%2.31B | 12.90%3.29B |
| Operating expense | 7.16%12.25B | -4.84%11.43B | -2.88%2.94B | -6.49%2.88B | -3.32%2.8B | -6.57%2.82B | 4.36%12.01B | -1.21%3.03B | 3.63%3.08B | 10.34%2.89B |
| Staff costs | -0.59%1.67B | -1.17%1.68B | ---- | ---- | ---- | ---- | 2.16%1.7B | ---- | ---- | ---- |
| Selling and administrative expenses | 11.01%8.67B | -7.53%7.81B | -5.88%2.02B | -10.49%1.98B | -4.85%1.92B | -8.68%1.89B | 7.88%8.45B | 1.04%2.14B | 10.82%2.21B | 14.91%2.02B |
| -Selling and marketing expense | 11.01%8.67B | -7.53%7.81B | -5.88%2.02B | -10.49%1.98B | -4.85%1.92B | -8.68%1.89B | 7.88%8.45B | 1.04%2.14B | 10.82%2.21B | 14.91%2.02B |
| Research and development costs | -29.74%137M | -7.14%195M | ---- | ---- | ---- | ---- | -45.17%210M | ---- | ---- | ---- |
| Depreciation and amortization | 11.18%179M | -0.62%161M | ---- | ---- | ---- | ---- | 14.89%162M | ---- | ---- | ---- |
| -Depreciation | 11.18%179M | -0.62%161M | ---- | ---- | ---- | ---- | 14.89%162M | ---- | ---- | ---- |
| Other operating expenses | 0.51%1.59B | 6.11%1.58B | 6.28%-1.12B | 3.68%901M | 0.23%875M | -1.91%923M | 0.07%1.49B | 4.56%-1.19B | -11.05%869M | 1.04%873M |
| Operating profit | -21.50%4.85B | 137.72%6.18B | -6.17%1.75B | 245.58%1.12B | 432.16%2.12B | 7.41%1.19B | 10.18%2.6B | 338.59%1.86B | -193.45%-770M | 35.84%398M |
| Net non-operating interest income (expenses) | -27.62%-231M | 0.55%-181M | 0.00%-44M | 2.13%-46M | 2.17%-45M | -2.22%-46M | 9.90%-182M | 4.35%-44M | 4.08%-47M | 13.21%-46M |
| Non-operating interest income | -3.45%56M | -12.12%58M | -12.50%14M | -6.25%15M | -11.76%15M | -17.65%14M | -12.00%66M | -11.11%16M | -15.79%16M | -10.53%17M |
| Non-operating interest expense | 20.08%287M | -3.63%239M | -3.33%58M | -3.17%61M | -4.76%60M | -3.23%60M | -10.47%248M | -6.25%60M | -7.35%63M | -12.50%63M |
| Net investment income | -77.11%138M | -13.49%603M | 983.33%260M | 55.72%-147M | -54.39%156M | -49.62%334M | 17.94%697M | -91.27%24M | -337.14%-332M | 470.00%342M |
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | 0 | 1M | -11M | 0 | 0 | |||||
| Income from associates and other participating interests | 245.74%325M | -64.12%94M | -140.38%-42M | -13.64%38M | 0.00%64M | -32.00%34M | -14.38%262M | 1,833.33%104M | -42.11%44M | -46.67%64M |
| Special income (charges) | -83.53%-3.25B | -657.69%-1.77B | -1,316.51%-1.33B | -184.21%-108M | 76.36%-52M | -237.65%-287M | 82.34%-234M | 120.64%109M | 90.93%-38M | 17.91%-220M |
| Less:Restructuring and mergern&acquisition | ---- | --0 | --0 | ---- | ---- | --0 | -78.05%36M | -99.39%1M | ---1M | --1M |
| Less:Other special charges | -35.21%528M | 1,281.36%815M | 313.95%368M | 176.92%108M | -63.38%52M | 474.00%287M | -91.17%59M | -169.35%-172M | -7.14%39M | -47.01%142M |
| Less:Write off | 184.55%2.73B | 589.21%958M | 1,445.16%958M | ---- | ---- | ---- | -71.81%139M | -46.55%62M | --0 | ---- |
| Other non-operating income (expenses) | -80.58%20M | 615.00%103M | 325.00%99M | -20.00%12M | -50.00%-12M | -76.47%4M | -66.67%-20M | -37.50%-44M | 15M | -8M |
| Income before tax | -63.36%1.84B | 61.01%5.02B | -65.94%686M | 178.14%883M | 319.59%2.23B | -28.11%1.23B | 81.55%3.12B | 2,065.59%2.01B | -291.53%-1.13B | 287.59%531M |
| Income tax | -23.60%1.02B | 1,475.29%1.34B | 563.89%167M | 181.52%278M | 284.70%704M | -31.90%190M | -81.56%85M | -300.00%-36M | -266.34%-341M | 273.47%183M |
| Net income | -77.84%816M | 21.36%3.68B | -74.73%518M | 176.78%605M | 339.19%1.52B | -27.37%1.04B | 141.56%3.03B | 2,670.27%2.05B | -304.68%-788M | 289.89%347M |
| Net income continuous operations | -77.82%817M | 21.39%3.68B | -74.68%519M | 176.68%605M | 337.93%1.52B | -27.37%1.04B | 141.37%3.03B | 2,633.33%2.05B | -304.94%-789M | 295.45%348M |
| Noncontrolling interests | -4,868.42%-944M | -18.75%-19M | -25.00%-5M | 0.00%-5M | -25.00%-5M | -33.33%-4M | -45.45%-16M | -33.33%-4M | -66.67%-5M | -100.00%-4M |
| Net income attributable to the company | -52.42%1.76B | 21.34%3.7B | -74.54%523M | 177.78%609M | 336.86%1.53B | -27.22%1.04B | 140.54%3.05B | 2,533.33%2.05B | -301.80%-783M | 288.89%350M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | -52.42%1.76B | 21.34%3.7B | -74.54%523M | 177.78%609M | 336.86%1.53B | -27.22%1.04B | 140.54%3.05B | 2,533.33%2.05B | -301.80%-783M | 288.89%350M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | -52.19%136.66 | 24.79%285.85 | -73.85%40.38 | 180.26%47.08 | 349.45%118.07 | -24.96%80.32 | 141.07%229.06 | 2,544.01%154.41 | -301.72%-58.66 | 289.76%26.27 |
| Diluted earnings per share | -52.19%136.66 | 24.79%285.85 | -73.85%40.38 | 180.17%47.0274 | 350.37%118.0677 | -24.96%80.32 | 141.07%229.06 | 2,544.01%154.41 | -301.86%-58.66 | 288.96%26.2159 |
| Dividend per share | 16.67%70 | 20.00%60 | 0.00%30 | 0 | 50.00%30 | 0 | 25.00%50 | 50.00%30 | 0 | 0.00%20 |
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |